Browsing Tag
Ocrevus
2 posts
Roche (SIX: ROP) sales rise 7% as pipeline hopes meet a near-record valuation
Roche delivered 7% constant-currency Q3 sales growth and maintained 2026 guidance as newer medicines offset patent erosion. With ROP touching a 52-week high and key medicines still awaiting regulatory decisions, pipeline conversion is becoming the next valuation test.
FDA approves Genentech’s Ocrevus for multiple sclerosis treatment
In a landmark decision, the US Food and Drug Administration (FDA) has granted approval to Genentech, a subsidiary…